BNC Korea

Company

BNC Korea develops 2 assets, the furthest in clinical trials with no phase (KL-001 in sarcopenia). Mostly microbiome.

2
Assets
Furthest stage: Clinical, no phase; 0
Trials: 3
Signals

Pipeline

2

KL-001
Postbiotic based on Lactiplantibacillus plantarum KM2 intended to improve muscle strength.
Clinical, no phase, Microbiome, sarcopenia, Partner
KMBR-001
Stage not known, Microbiome, Partner

Full company profiles: pipeline, trials, funding and people.

In the full profile

Signals3
Similar companies6